[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS: Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol; 2009 Mar;112(3):444-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
  • OBJECTIVE: Intraperitoneal (IP) chemotherapy prolongs survival in optimally reduced ovarian cancer patients.
  • For patients in whom optimal debulking cannot be achieved, one could incorporate IP therapy post-operatively if the cancer was optimally debulked following neoadjuvant chemotherapy.
  • METHODS: Women with adenocarcinoma by biopsy or cytology with stage III/IV (pleural effusions only) epithelial ovarian, fallopian tube or primary peritoneal carcinoma that presented with bulky disease were treated with neoadjuvant intravenous (IV) paclitaxel 175 mg/m2 and carboplatin AUC 6 q 21 daysx3 cycles followed by surgery (if >/=50% decrease in CA125).
  • Fifty-six were evaluated for neoadjuvant chemotherapy toxicities.
  • Twenty-six patients received post-cytoreduction chemotherapy.
  • PFS and OS for the 26 patients who received IV/IP chemotherapy is 29 and 34 months respectively.

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):327-31 [2351315.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1335-41 [2199620.001]
  • [Cites] Gynecol Oncol. 1991 Feb;40(2):103-6 [2010101.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):146-50 [1894174.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1485-91 [1355523.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):166-72 [8418230.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(4):198-202 [8398914.001]
  • [Cites] Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80 [8166218.001]
  • [Cites] Gynecol Oncol. 1994 Apr;53(1):33-7 [8175019.001]
  • [Cites] Obstet Gynecol Clin North Am. 1994 Mar;21(1):195-212 [8015764.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):93-9 [9889037.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2489-97 [15590951.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):10-5 [15790431.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):480-90 [17166564.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):265-70 [18055006.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):271-5 [18164380.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2585-91 [11745193.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18(3):235-8 [3542268.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):282-90 [3276825.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):347-58 [3134277.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Gynecol Oncol. 1990 Mar;36(3):306-11 [2180794.001]
  • (PMID = 19138791.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA86780; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA35262; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA105409; United States / NCI NIH HHS / CA / U10 CA035262; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS423205; NLM/ PMC3513943
  •  go-up   go-down


2. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res; 2006 Sep 15;12(18):5503-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • PURPOSE: This open-label study assessed the safety and immunogenicity of two doses and two routes of the anti-idiotypic monoclonal antibody abagovomab (formerly ACA125) in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • EXPERIMENTAL DESIGN: Eligible patients from the three participating institutions were any stage at diagnosis, had relapsed, and had complete or partial response to additional chemotherapy.
  • A phase III randomized study with abagovomab (2.0 mg s.c.) is warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. CA-125 Antigen / immunology. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibody Formation / drug effects. Cohort Studies. Drug Administration Routes. Female. Histocompatibility Antigens Class II / blood. Histocompatibility Antigens Class II / metabolism. Humans. Interferon-gamma / biosynthesis. Middle Aged. T-Lymphocytes / immunology. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2007 Jul 1;13(13):4026; author reply 4026-7 [17606738.001]
  • (PMID = 17000686.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA89333; United States / NCI NIH HHS / CA / P01 CA052477-13
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CA-125 Antigen; 0 / Histocompatibility Antigens Class II; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


3. Tiersten AD, Sill MW, Knight D, Muggia F, Garcia AA, Swensen R, Warshal DP, Mannel RS, Fracasso PM: A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol; 2010 Sep;118(3):303-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
  • PURPOSE: Dose-dense regimens have been shown to improve outcome when given as adjuvant therapy to patients with breast cancer compared with their three weekly counterparts.
  • We investigated the feasibility of a dose-dense regimen with carboplatin/paclitaxel followed by pegfilgrastim in patients with advanced ovarian cancer.
  • PATIENTS AND METHODS: Women with untreated Stage III or IV epithelial ovarian, (fallopian) tubal, or primary peritoneal cancer were treated with carboplatin area under the curve (AUC) 5 and paclitaxel 175 mg/m(2) day one, and pegfilgrastim 6 mg day two every 2 weeks for six cycles.
  • Thirty-one patients completed six or more cycles of therapy.
  • The dose limiting toxicities resulting in treatment discontinuation included: grade 3 and 4 neuropathy, grade 4 thrombocytopenia, grade 4 thrombocytopenia/grade 3 febrile neutropenia, and grade 4 supraventricular tachycardia.
  • However, based on dose limiting toxicities occurring when administering 6 cycles of treatment, it is not feasible.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3374-88 [10550131.001]
  • [Cites] Lancet. 2009 Oct 17;374(9698):1331-8 [19767092.001]
  • [Cites] Gynecol Oncol. 2003 Jan;88(1):51-7 [12504627.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1431-9 [12668651.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Ann Intern Med. 1973 Oct;79(4):604-5 [4748282.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1732-42 [8411257.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1589-99 [7602348.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1858-69 [9164196.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 10):S10-3-S10-10 [9275000.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1205-11 [9719081.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):296-300 [15661211.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):354-61 [17499348.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):707-12 [19223898.001]
  • [Cites] Gynecol Oncol. 2009 Aug;114(2):215-8 [19446318.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 20547415.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / U10 CA027469-19
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  • [Other-IDs] NLM/ NIHMS214931; NLM/ PMC2918716
  •  go-up   go-down


Advertisement
4. Onda T, Kobayashi H, Nakanishi T, Hatae M, Iwasaka T, Konishi I, Shibata T, Fukuda H, Kamura T, Yoshikawa H: Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol; 2009 Apr;113(1):57-62
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
  • BACKGROUND: To assess the safety and efficacy of neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) for müllerian carcinomas, such as ovarian, tubal, and peritoneal cancers, and to determine whether we can omit diagnostic laparoscopy before treatment initiation, a feasibility study was performed.
  • METHODS: Eligible patients had presumed stage III/IV müllerian carcinomas clinically diagnosed by imaging studies, cytology, and tumor markers.
  • Four cycles of paclitaxel and carboplatin were administered as NAC, followed by interval debulking surgery and an additional 4 cycles of chemotherapy.
  • The primary end point was the proportion of patients achieving clinical complete remission (cCR) among all stage III/IV müllerian carcinomas confirmed by diagnostic laparoscopy.
  • The PPV of overall clinical diagnosis for the tumor origin, histology, and stage was 95% (53/56).
  • Fifty-three patients received the protocol treatment starting with NAC.
  • Twenty-two patients (42%) achieved cCR after completion of the treatment.
  • CONCLUSION: NAC without diagnostic laparoscopy for advanced müllerian carcinomas holds sufficient promise to be compared with direct surgery in a phase III trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Feasibility Studies. Female. Humans. Middle Aged. Mixed Tumor, Mullerian / drug therapy. Mixed Tumor, Mullerian / surgery. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Patient Compliance

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2009 Aug;114(2):371; author reply 371-2 [19403162.001]
  • (PMID = 19181369.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00112086
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Leath CA 3rd, Numnum TM, Straughn JM Jr, Rocconi RP, Huh WK, Kilgore LC, Partridge EE: Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: a retrospective university experience. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):998-1002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: a retrospective university experience.
  • The aim is to evaluate disease-free (DFS) and overall survival (OS) of patients with fallopian tube carcinoma (FTCA) treated with adjuvant chemotherapy.
  • An Institutional Review Board approved retrospective review identified 38 patients with FTCA that received adjuvant chemotherapy following primary surgery from 1975 to 2001.
  • Twenty patients (53%) had FIGO stage III/IV FTCA.
  • Adjuvant chemotherapeutic regimens consisted of melphalan in 11 patients, platinum-based chemotherapy without paclitaxel in 17 patients, and the combination of paclitaxel and platinum in 10 patients.
  • Although DFS was similar for the three chemotherapy cohorts (P= 0.19), patients receiving paclitaxel had superior OS compared to patients receiving either melphalan (P= 0.02) or platinum without paclitaxel (P= 0.04).
  • Of the twenty patients with stage III/IV disease, 55% of patients had optimal cytoreduction performed at their initial surgery.
  • [MeSH-major] Carcinoma / therapy. Fallopian Tube Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome. Universities

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367322.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Gemignani ML, Hensley ML, Cohen R, Venkatraman E, Saigo PE, Barakat RR: Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol; 2001 Jan;80(1):16-20
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
  • OBJECTIVE: The objective of this study was to determine the clinical outcomes of patients with fallopian tube carcinoma treated with paclitaxel-based combination chemotherapy following primary cytoreductive surgery.
  • METHODS: Twenty-four patients with the diagnosis of primary tubal adenocarcinoma treated between 1993 and 1998 were identified through the gynecology service database and the Memorial Sloan-Kettering Cancer Center tumor registry.
  • Medical records were reviewed for information on age, stage, chemotherapy regimen, surgical intervention, relapse, and survival.
  • All patients had their histologic material initially read or reviewed at Memorial Sloan-Kettering Cancer Center prior to treatment.
  • The original slides were reviewed again by one of the authors (P.E.S.) to confirm the diagnosis of primary fallopian tube cancer.
  • Distribution by stage was as follows: four patients (17%) were Stage I, three patients (12%) were Stage II, 16 patients (67%) were Stage III, one patient (4%) was Stage IV.
  • Sixteen patients (67%) had optimal cytoreduction at the time of initial surgery with residual disease less than 1 cm.
  • Following initial surgery, all patients were treated with paclitaxel-based chemotherapy for a median of five cycles.
  • Median follow-up from time of initial surgery was 24 months (range, 1-73 months).
  • CONCLUSION: Optimally cytoreduced patients with primary fallopian tube carcinoma treated with a paclitaxel-based chemotherapy regimen have an excellent possibility of survival.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Paclitaxel / administration & dosage. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • [CommentIn] Gynecol Oncol. 2002 Jan;84(1):185-6 [11749002.001]
  • (PMID = 11136563.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Harries M, Moss C, Perren T, Gore M, Hall G, Everard M, A'Hern R, Gibbens I, Jenkins A, Shah R, Cole C, Pizzada O, Kaye S: A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer; 2004 Aug 16;91(4):627-32
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
  • A total of 53 women with chemotherapy-naïve stage Ic-IV ovarian cancer were treated with four cycles of carboplatin area under the curve 7 every 3 weeks, followed by four cycles of paclitaxel 70 mg m(-2) (days 1, 8, and 15) and gemcitabine 1000 mg m(-2) (days 1 and 8) every 3 weeks.
  • In all, 37 (70%) had stage III/IV disease, with 22 (42%) having tumour >2 cm; 38 patients (72%) completed all planned treatment; 27 of the 32 (84%) patients with radiologically evaluable disease had partial or complete responses; and 30 of the 39 patients (77%) with elevated cancer antigen (CA) 125 had a greater than 75% fall in this value.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Area Under Curve. Carboplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Lung / drug effects. Lung / pathology. Middle Aged. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 1999 Nov;125(11):637-40 [10541971.001]
  • [Cites] Ann Oncol. 1998 Dec;9(12):1343-5 [9932166.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):699-708 [10793106.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):738-47 [11340581.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2329-34 [11094306.001]
  • [Cites] Anticancer Drugs. 2001 Sep;12(8):647-52 [11604551.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 1):17-9 [11840416.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):529-36 [12217790.001]
  • [Cites] Lancet. 2002 Aug 17;360(9332):505-15 [12241653.001]
  • [Cites] Lung Cancer. 2002 Oct;38(1):73-7 [12367796.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):266-9 [12648573.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2099-106 [12826431.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1530-3 [7932808.001]
  • [Cites] Semin Oncol. 1995 Oct;22(5 Suppl 12):88-90 [7481869.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):89-93 [8898175.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 1:35-41 [10219451.001]
  • [Cites] Ann Oncol. 1999 Jul;10(7):853-5 [10470434.001]
  • [Cites] Am J Clin Oncol. 1999 Oct;22(5):450-2 [10521056.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • (PMID = 15238984.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2364776
  •  go-up   go-down


8. Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM: Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol; 2010 Dec;119(3):451-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
  • BACKGROUND: The purpose of this study was to determine whether adding the anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to carboplatin/paclitaxel improved pathologic complete response (pCR) at reassessment surgery in epithelial ovarian, fallopian tube, or primary peritoneal cancers (OFPC).
  • METHODS: Patients with stage III-IV OFPC initiated treatment within 12 weeks of initial cytoreductive surgery or, after histologic confirmation of diagnosis, neoadjuvantly.
  • Treatment included paclitaxel (175 mg/m²) and carboplatin (AUC 6) every 3 weeks for up to 6 cycles, plus oral erlotinib 150 mg daily.
  • The primary objective was to determine whether the pCR rate at reassessment surgery was at least 60% after optimal cytoreduction at initial surgery (< 1cm residual disease), or at least 40% after suboptimal cytoreduction (at least 1cm residual disease) using a two-stage design (alpha=0.10, beta=0.10).
  • RESULTS: The study population included 56 patients with stage III-IV OFPC.
  • Twenty-eight patients had protocol therapy after optimal cytoreduction (stratum I), 23 had protocol therapy either after suboptimal cytoreduction (stratum II), and 5 received neoadjuvant therapy prior to cytoreduction (stratum III).
  • CONCLUSIONS: Among unselected patients, erlotinib plus carboplatin-paclitaxel did not improve pCR rates compared with historical experience with carboplatin-paclitaxel alone in patients with stage III-IV OFPC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant. Disease-Free Survival. Erlotinib Hydrochloride. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / genetics. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Gene Amplification / drug effects. Genes, erbB-1 / drug effects. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Quinazolines / administration & dosage. Quinazolines / adverse effects. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] Cancer. 2008 May 15;112(10):2289-300 [18393325.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Drugs. 2004;64(21):2475-92 [15482004.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):409-22 [10458260.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1572-8 [15746062.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5235-46 [16051966.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5539-48 [16061871.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):785-92 [16174225.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1441-8 [16211241.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8637-43 [16361548.001]
  • [Cites] Expert Opin Pharmacother. 2006 Feb;7(2):177-93 [16433583.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):607-10 [16554736.001]
  • [Cites] J Mol Med (Berl). 2006 Aug;84(8):671-81 [16607561.001]
  • [Cites] Drugs. 2006;66(15):2005-14; discussion 2015-6 [17100412.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1545-52 [17442998.001]
  • [Cites] J Clin Oncol. 2007 Jul 10;25(20):2873-83 [17617518.001]
  • [Cites] Drugs. 2007;67(17):2585-607 [18034592.001]
  • [Cites] J Cell Biochem. 2008 Feb 1;103(2):556-63 [17546586.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2749-55 [18438878.001]
  • [Cites] Cancer. 2008 Dec 15;113(12):3298-306 [19006196.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1419-25 [19224846.001]
  • [Cites] Gynecol Oncol. 2009 Apr;113(1):21-7 [19162309.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • (PMID = 20837357.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000096; United States / NCI NIH HHS / CM / N01 CM017103; United States / NCI NIH HHS / CA / N01CM62204; United States / NCI NIH HHS / CM / N01 CM062204; United States / NCI NIH HHS / CM / N01-CM-62204; United States / NCRR NIH HHS / RR / M01-RR-00096
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS230455; NLM/ PMC3446254
  •  go-up   go-down


9. Micha JP, Goldstein BH, Rettenmaier MA, Mattison J, Graham C, Birk CL, Brown JV: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol; 2004 Sep;94(3):719-24
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
  • OBJECTIVE: The purpose of this study was to determine the feasibility, response rate, and toxicity of paclitaxel, carboplatin, and gemcitabine as an outpatient regimen in the treatment of ovarian/non-ovarian and tubal adenocarcinoma.
  • This is the largest completed study using this regimen as first-line treatment of these patients.
  • After six cycles of treatment, responders were eligible for an additional three cycles of paclitaxel and gemcitabine.
  • RESULTS: Fifty-seven patients (median age = 58; range 41-81) with stage III/IV epithelial carcinoma of the ovary, fallopian tube, and peritoneum received a total of 476 cycles of chemotherapy.
  • Grades 3 and 4 neutropenia developed in 19.7% and 9% of cycles while grades 3 and 4 thrombocytopenia developed in 4.2% and 1.3% of the cycles.
  • Twenty-two patients developed some degree of neuropathy, although there was no reported interference with activities of daily living.
  • CONCLUSIONS: This report represents the largest completed study in the world employing this triplet regimen in the first-line treatment of advanced stage epithelial ovarian, fallopian tube, or peritoneal cancer patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Pilot Projects


10. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM: Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol; 2010 Jan 1;28(1):154-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
  • PURPOSE New strategies are needed to improve outcomes for patients with advanced ovarian cancer.
  • PATIENTS AND METHODS An open-label, phase II clinical trial was conducted in newly diagnosed patients with stage > or = IC epithelial müllerian tumors.
  • Fifty-one patients (82%) were optimally surgically cytoreduced before treatment.
  • Forty-five women (73%) had ovarian cancer, 10 (16%) had peritoneal cancer, four (6%) had fallopian tube cancers, and three (5%) had uterine papillary serous tumors.
  • The majority of patients (90%) had stage III or IV disease.
  • Treatment was associated with two pulmonary embolisms and two GIPs, all occurring during the chemotherapy phase of treatment (364 total cycles).
  • No grade 4 toxicities were seen during maintenance bevacizumab treatment.
  • CONCLUSION The regimen of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab is feasible, safe, and worthy of future study in advanced ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917843.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Onda T, Matsumoto K, Shibata T, Sato A, Fukuda H, Konishi I, Kamura T, Yoshikawa H, Japan Clinical Oncology Group: Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol; 2008 Jan;38(1):74-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.
  • On the basis of promising results of neoadjuvant chemotherapy (NAC) in our previous study (JCOG0206), we have been performing a Phase III study of treatment starting with NAC versus standard treatment starting with primary debulking surgery (PDS) for Stage III/IV müllerian carcinomas (ovarian, tubal and peritoneal carcinomas) since November 2006.
  • The purposes are to prove the non-inferiority of the efficacy and to show the decrease in adverse effects resulting from reduced surgical invasiveness of treatment starting with NAC.
  • NAC arm patients undergo four cycles of NAC with paclitaxel plus carboplatin followed by interval debulking surgery and an additional four cycles of postsurgical chemotherapy.
  • Standard arm patients undergo PDS and eight cycles of postsurgical chemotherapy with or without interval debulking surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / therapy. Ovarian Neoplasms / therapy. Ovariectomy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258715.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Rosen AC, Ausch C, Klein M, Graf AH, Metzenbauer M, Philipp K, Reiner A: p53 expression in fallopian tube carcinomas. Cancer Lett; 2000 Aug 1;156(1):1-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 expression in fallopian tube carcinomas.
  • Sixty-three women treated for primary carcinoma of the fallopian tube (PFTC) from 1980-1995 were retrospectively analyzed to study the impact of p53 expression on survival in primary carcinoma of the fallopian tube.
  • Twenty-four (38%) patients were FIGO stage I, 11 (18%) stage II, 19 (30%) stage III and nine (14%) stage IV.
  • Adjuvant therapy consisted of either chemotherapy (n: 31; 49%) or irradiation (n: 21; 33%).
  • For stages I+II and III+IV the 5-year survival rate was 59 and 19%, respectively (P<0.00001).
  • [MeSH-major] Fallopian Tube Neoplasms / genetics. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10840153.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


13. Yu AJ, Fang SH, Gao YL: [Analysis of therapeutic result and prognostic factor in primary fallopian tube carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):789-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of therapeutic result and prognostic factor in primary fallopian tube carcinoma].
  • OBJECTIVE: To investigate the impact of treatment modality and clinicopathologic profile on prognosis in primary fallopian tube carcinoma.
  • METHODS: The data of 64 cases with primary fallopian tube carcinoma treated between January 1991 and June 2006 were analyzed.
  • However, there was no significant difference in 3-year and 5-year survival rate between the group with pelvic lymphadenectomy and the group without (84.2% vs. 69.2%, P = 0.4667; 63.1% vs. 53.8%, P = 0.459), and also between the group treated using CAP/CP regimen and the group by TP regimen for chemotherapy (81.8% vs. 80.0%, P = 0.8946; 59.1% vs. 60.0% P = 0.9582).
  • It was found that the 5-year survival was correlated with FIGO stage (III-IV vs. I - II, P = 0.0197), differentiation grade (G3 vs. G1 + G2, P = 0.003), pathologic type (other type vs. serous, P = 0.0494), lymph nodes status (positive vs. negative, P = 0.0295).
  • CONCLUSION: Surgical staging, optimal cytoreduction, differentiation grade, pathologic type, lymph node status are important factors influencing the 5-year survival in primary fallopian tube carcinoma.
  • Pelvic lymphadenectomy is necessary and feasible to perform during the procedure of surgical staging and cytoreduction.
  • CAP/CP and TP regiment are similarly effective in adjuvant chemotherapy for primary fallopian tube carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / surgery. Fallopian Tube Neoplasms / surgery. Hysterectomy / methods. Ovariectomy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Survival Rate. Taxoids / therapeutic use

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396696.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol; TP protocol
  •  go-up   go-down


14. Kosary C, Trimble EL: Treatment and survival for women with Fallopian tube carcinoma: a population-based study. Gynecol Oncol; 2002 Aug;86(2):190-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and survival for women with Fallopian tube carcinoma: a population-based study.
  • OBJECTIVE: The objective of this study was to evaluate treatment and survival for women with fallopian tube carcinoma in a population-based data set.
  • METHODS: Using the National Cancer Institute's Surveillance, Epidemiology, and End Results program, we identified 416 women with fallopian tube carcinoma diagnosed between 1990 and 1997.
  • We analyzed treatment and 5-year relative survival.
  • We also compared survival to that of 9032 women with epithelial ovarian cancer diagnosed between 1991 and 1997.
  • RESULTS: Almost half of those diagnosed with stage I/II disease did not undergo surgical evaluation of lymph nodes.
  • Most women with stage I/II disease were treated with surgery alone, while most women with stage III/IV disease were treated with surgery and chemotherapy.
  • Five-year relative survival by FIGO stage was as follows: stage I (N = 102), 95%; stage II (N = 29), 75%; stage III (N = 52), 69%; stage IV (N = 151), 45%.
  • CONCLUSIONS: We observed better survival, stage by stage, for women with fallopian tube carcinoma than for women with epithelial ovarian cancer in this population-based data set.
  • It is possible that some patients with advanced, bulky carcinoma arising in the fallopian tube may have been classified as having ovarian or primary peritoneal cancer.
  • Women with fallopian tube cancer should be treated in accordance with the same guidelines for surgical staging, debulking, and adjuvant chemotherapy as for women with epithelial ovarian cancer.
  • Further studies, both laboratory and clinical, are needed to delineate the differences between fallopian and ovarian cancers.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / therapy. Fallopian Tubes. Genital Neoplasms, Female / mortality. Genital Neoplasms, Female / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy. SEER Program. Survival Analysis. Treatment Outcome. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12144827.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Vasey P, Kaye S, Paul J, Rustin G, Wilson R, Guastalla JP, Pujade-Lauraine E, Gore M, Gabra H, Carty K, Scottish Gyn Cancer Trials Group: A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers. J Clin Oncol; 2004 Jul 15;22(14_suppl):5017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers.
  • Erlotinib (Tarceva™, a highly potent reversible HER1/EGFR tyrosine-kinase inhibitor) has exhibited additive antitumor activity in combination with platinum and taxane chemotherapy preclinically, and single agent activity in heavily pretreated patients (pts).
  • In pts with EOC, D with C has a tolerable safety profile, similar efficacy as paclitaxel with C, and is an acceptable first-line option (Vasey ASCO 2002).
  • RESULTS: 39 pts (median age 59 years; stage III/IV EOC) have been treated (median 5 cycles).
  • 1/12 pts in Cohort 1 (50mg E + DC) had a drug-related DLT (plantar-palmar erythrodysethesia [PPE]).
  • In Cohort 2, 4/12 pts on 100mg E with DC had significant skin toxicity (intolerable grade 2 or 3 rash) and 1 pt had grade 3 diarrhea despite loperamide treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015481.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Konner JA, Grabon D, Pezzulli S, Iasonos A, Sabbatini P, Hensley M, Bell-McGuinn K, Tew W, Spriggs D, Aghajanian C: A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer.
  • : 5539 Background: IP cisplatin (Cis) plus IV/IP paclitaxel (Tax) is a standard therapy for optimally debulked ovarian cancer.
  • Activity of Bev in recurrent ovarian cancer has been reported in phase II trials.
  • In this study IP Cis and IV/IP Tax are combined with IV Bev as front-line therapy.
  • METHODS: Patients with optimal (<1 cm residual), FIGO stage II or III, epithelial ovarian, fallopian tube, or peritoneal cancer, acceptable organ function, and KPS ≥ 70% are eligible.
  • Patients receive 6 cycles of chemotherapy plus Bev: Tax 135 mg/m<sup>2</sup> IV over 3 hours on Day 1, Cis 75 mg/m<sup>2</sup> IP on Day 2, Tax 60 mg/m<sup>2</sup> IP on Day 8, Bev 15 mg/kg IV on Day 1 (starting cycle 2).
  • Bev is continued every 3 weeks for 17 treatments after chemotherapy is complete.
  • The primary endpoint is safety and tolerability, determined by whether at least 60% of patients complete the prescribed 6 cycles of cytotoxic chemotherapy without unacceptable toxicity.
  • RESULTS: Thirty-nine women [median age 56 (40-69)] have been treated on study: 26 (67%) completed 6 IV/IP cycles; 5 (13%) are receiving ongoing IV/IP treatment; 4 (10%) experienced IP port malfunction (3 finished 5 IV/IP cycles, 1 came off study for port revision); 3 (8%) switched from IP Cis to IV carboplatin due to grade 3 nephrotoxicity in cycle 1 (n = 2) or grade 3 hypertension in cycle 6 (n = 1); and 1 (2.5%) patient died following rectosigmoid anastomotic dehiscence during cycle 4.
  • Grade 3/4 treatment-related toxicities include hypertension (10%), vasovagal events (10%), neutropenia (26%), nausea/vomiting (10%), and hypomagnesemia (8%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Liapis A, Bakalianou K, Mpotsa E, Salakos N, Fotiou S, Kondi-Paffiti A: Fallopian tube malignancies: A retrospective clinical pathological study of 17 cases. J Obstet Gynaecol; 2008 Jan;28(1):93-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube malignancies: A retrospective clinical pathological study of 17 cases.
  • Carcinomas were staged according to the FIGO criteria; assignment of stage was made on the operative data and the pathological findings.
  • Four patients had Stage I tumour (23.5%), six had Stage II (35.4%), five patients had Stage III (29.4%) and two had Stage IV (11.7%).
  • The histological type of all our specimens was primary papillary adenocarcinoma of the fallopian tube.
  • Primary fallopian tube cancer (PFTC) is a rare gynaecological malignancy, similar to ovarian cancer, but with poorer prognosis.
  • The treatment was surgical followed by adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma, Papillary / epidemiology. Fallopian Tube Neoplasms / epidemiology
  • [MeSH-minor] Aged. Combined Modality Therapy. Databases, Factual. Female. Greece / epidemiology. Humans. Medical Records. Middle Aged. Neoplasm Staging. Pathology Department, Hospital. Pregnancy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259909.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Singhal P, Odunsi K, Rodabaugh K, Driscoll D, Lele S: Primary fallopian tube carcinoma: a retrospective clinicopathologic study. Eur J Gynaecol Oncol; 2006;27(1):16-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma: a retrospective clinicopathologic study.
  • INTRODUCTION: Primary fallopian tube carcinoma is a rare tumor.
  • The aim of this study was to evaluate clinical characteristics and management of fallopian tube malignancies at a large tertiary care cancer institute.
  • METHODS: A retrospective review of the Tumor Registry was conducted to identify all primary fallopian tube carcinomas between 1980 and 2001.
  • RESULTS: Thirty-five patients had histology consistent with fallopian tube carcinoma.
  • Five patients (14%) were Stage I, seven patients (20%) Stage II, 17 patients (49%) Stage III and six patients (17%) Stage IV.
  • Thirty-two (91%) patients received adjuvant chemotherapy and 77% received platinum-based chemotherapy.
  • The 5-year survival rate was 64% for Stage I, 42% for Stage II, 32% for Stage III, and 17% for Stage IV.
  • CONCLUSIONS: Fallopian tube malignancies are rare and carry a poor prognosis.
  • More extensive research needs to be performed to have definitive etiologic, diagnostic and treatment guidelines.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / pathology. Cause of Death. Fallopian Tube Neoplasms / mortality. Fallopian Tube Neoplasms / pathology. Second-Look Surgery / trends
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Combined Modality Therapy. Female. Gynecologic Surgical Procedures / methods. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Registries. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550961.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Schneider C, Wight E, Perucchini D, Haller U, Fink D: Primary carcinoma of the fallopian tube. A report of 19 cases with literature review. Eur J Gynaecol Oncol; 2000;21(6):578-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the fallopian tube. A report of 19 cases with literature review.
  • Primary carcinoma of the fallopian tube is the rarest cancer of the female genital tract with an incidence of 0.5% of all gynecologic tumors.
  • Due to similarity of the clinical presentation the staging and therapeutic management have been adapted to that of ovarian cancer.
  • We retrospectively evaluated all the 19 patients who had been diagnosed with primary carcinoma of the fallopian tube at the Department of Obstetrics and Gynecology of the University of Zurich between 1977 and 1998.
  • At the time of diagnosis the median age was 62 (46-87) years.
  • Twelve (63%) women revealed FIGO stage III-IV, whereas four (21%) and three (16%) patients were diagnosed in stage I and stage II, respectively.
  • The 5-year survival rate was 22% for all FIGO stages and 80% for stage I.
  • None of the patients with stage III and IV survived 5 years.
  • Ovarian cancer and primary carcinoma of the fallopian tube are similar in many aspects.
  • Both carcinomas have a similar age distribution, show an increase among nulliparous women, are often of serous papillary histology, have a poor prognosis with stage and residual tumor size as important prognostic factors, and respond initially well to platinum-based chemotherapy.
  • Nevertheless, there appears to be a difference between the two diseases: primary carcinoma of the fallopian tube is more often diagnosed in an earlier stage.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Switzerland / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11214613.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 38
  •  go-up   go-down


20. Wagenaar HC, Pecorelli S, Vergote I, Curran D, Wagener DJ, Kobierska A, Bolis G, Bokkel-Huinink WT, Lacave AJ, Madronal C, Forn M, de Oliveira CF, Mangioni C, Nooij MA, Goupil A, Kerbrat P, Marth CH, Tumolo S, Herben MG, Zanaboni F, Vermorken JB: Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer. Eur J Gynaecol Oncol; 2001;22(3):187-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.
  • OBJECTIVE: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease.
  • RESULTS: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial.
  • Fourteen patients had FIGO stage III, and ten had stage IV disease.
  • WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia.
  • At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease.
  • The median time to progression was 13 months for all patients.
  • CONCLUSION: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Europe. Female. Humans. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11501769.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA: A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol; 2008 Aug;110(2):140-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
  • OBJECTIVE: Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer.
  • RESULTS: Forty-one patients were enrolled in this study; 40 received treatment and were evaluable for toxicity, and 38 were evaluable for PFS.
  • Grade 3/4 treatment-related toxicities included febrile neutropenia (12.5%), rash (2.5%), hypersensitivity reaction (7.5%), and hypomagnesemia (12.5%).
  • CONCLUSIONS: The combination of cetuximab with paclitaxel and carboplatin is adequately tolerated as primary therapy for ovarian cancer but did not demonstrate prolongation of PFS when compared to historical data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cetuximab. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554700.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA052477
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; PQX0D8J21J / Cetuximab
  •  go-up   go-down


22. Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M: Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2007 Oct 1;25(28):4466-71
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
  • PURPOSE: This study was undertaken to assess if prolonged paclitaxel administration in combination with cisplatin improves overall survival (OS) in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHODS: Eligible patients with suboptimal stage III or IV EOC, fallopian tube, or primary peritoneal cancer were randomly allocated to receive six cycles of cisplatin 75 mg/m2 and either paclitaxel 135 mg/m2 during 24 hours (arm 1) or paclitaxel 120 mg/m2 during 96 hours (arm 2).
  • The results of treatment with cisplatin and paclitaxel are not significantly improved by prolonging the paclitaxel infusion from 24 to 96 hours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Infusions, Intravenous. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906207.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA, Gynecologic Oncology Group Study: A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol; 2008 Dec;111(3):455-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
  • OBJECTIVES: To estimate the anti-tumor activity and toxicity of paclitaxel poliglumex (PPX) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (EOC) in second or third line treatment.
  • At a planned analysis following first stage accrual, the dose was reduced to 175 mg/m(2) Cohort 2) for additional accrual to 78 patients.
  • The most frequent grade III or IV toxicities in cohort 2 were: neutropenia (24%/20%), constitutional (8%/0%), gastrointestinal (6%/0%), and neuropathy (24%/0%).
  • CONCLUSION: PPX at 175 mg/m(2) every 21 days has a modest activity of limited duration when given as second or third line therapy in patients with epithelial ovarian or primary peritoneal cancer.
  • The incidence of neuropathy using this dose in recurrent ovarian cancer is higher than predicted from studies in other tumors with PPX.
  • The Gynecology Oncology Group (GOG) is currently exploring its use at 135 mg/m(2) every 28 days in a randomized trial evaluating maintenance chemotherapy in first remission.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Peritoneal Neoplasms / drug therapy. Polyglutamic Acid / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Dose-Response Relationship, Drug. Fallopian Tube Neoplasms / drug therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829087.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / paclitaxel poliglumex; 25513-46-6 / Polyglutamic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


24. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K, Japanese Gynecologic Oncology Group: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet; 2009 Oct 17;374(9698):1331-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
  • BACKGROUND: Paclitaxel and carboplatin given every 3 weeks is standard treatment for advanced ovarian carcinoma.
  • Attempts to improve patient survival by including other drugs have yielded disappointing results.
  • We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer.
  • METHODS: Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.
  • FINDINGS: 631 of the 637 enrolled patients were eligible for treatment and were included in the ITT population (dose-dense regimen, n=312; conventional regimen, n=319).
  • Median progression-free survival was longer in the dose-dense treatment group (28.0 months, 95% CI 22.3-35.4) than in the conventional treatment group (17.2 months, 15.7-21.1; hazard ratio [HR] 0.71; 95% CI 0.58-0.88; p=0.0015).
  • Overall survival at 3 years was higher in the dose-dense regimen group (72.1%) than in the conventional treatment group (65.1%; HR 0.75, 0.57-0.98; p=0.03).
  • 165 patients assigned to the dose-dense regimen and 117 assigned to the conventional regimen discontinued treatment early.
  • The frequency of grade 3 and 4 anaemia was higher in the dose-dense treatment group (214 [69%]) than in the conventional treatment group (137 [44%]; p<0.0001).
  • INTERPRETATION: Dose-dense weekly paclitaxel plus carboplatin improved survival compared with the conventional regimen and represents a new treatment option in women with advanced epithelial ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy


25. Hsu Y, Sood AK, Sorosky JI: Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol; 2004 Feb;27(1):14-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
  • All patients with primary ovarian, fallopian tube, or peritoneal malignancies treated with docetaxel and platinum at the University of Iowa between January 1996 and June 1999 were identified.
  • Controls, treated with paclitaxel and platinum, were matched for age, date of diagnosis, type of cancer, stage, and residual disease.
  • Nine (45%) had grade III or IV neutropenia and fever developed in two of these patients.
  • Grade III or IV thrombocytopenia developed in two patients.
  • In contrast, among the paclitaxel/carboplatin group, grade III or IV neutropenia developed in only three patients (p < 0.05) and grade III or IV thrombocytopenia developed in two patients.
  • In the paclitaxel/carboplatin group, 13 patients developed neuropathy compared to only 2 patients (10%) in the docetaxel/carboplatin group (p < 0.05).
  • There was no difference in the clinical response between the two treatment groups.
  • The therapeutic efficacy was equivalent between the two groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Case-Control Studies. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neutropenia / chemically induced. Peripheral Nervous System Diseases / chemically induced. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14758127.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement